Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Breast cancer adjuvant therapy

Executive Summary

NIH Consensus Conference, scheduled for Sept. 9-11 at institutes' Masur Auditorium. Consensus statement will address five questions: "Have adjuvant chemotherapy trials in breast cancer demonstrated an increase in survival in any group of patients?" * * "What are the significant adverse effects of adjuvant therapy?" I I"What is the role of endocrine treatment in adjuvant therapy of breast cancer?" * * "When should women with histologically negative axillary lymph nodes receive adjuvant therapy?" * * "What directions for future research are indicated?" Contact Peter Murphy: (301) 488-6555. . . .
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS008788

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel